Comparing SG&A Expenses: Eli Lilly and Company vs CRISPR Therapeutics AG Trends and Insights

A Decade of SG&A Expenses: Eli Lilly vs. CRISPR Therapeutics

In the ever-evolving pharmaceutical landscape, understanding the financial strategies of industry giants is crucial. Over the past decade, Eli Lilly and CRISPR Therapeutics have showcased contrasting trends in their Selling, General, and Administrative (SG&A) expenses. Eli Lilly, a stalwart in the industry, consistently allocated a significant portion of its budget to SG&A, peaking at nearly $7 billion in 2023. This reflects a steady commitment to maintaining its market presence and operational efficiency.

Conversely, CRISPR Therapeutics, a pioneer in gene-editing technology, exhibited a more dynamic trajectory. Starting with modest expenses in 2014, CRISPR's SG&A costs surged by over 1,400% by 2021, highlighting its aggressive growth strategy. However, a slight dip in 2023 suggests a strategic recalibration. This comparison underscores the diverse financial approaches within the pharmaceutical sector, driven by each company's unique market position and growth objectives.